One hundred and forty children with hematologic malignancies undergoing allogeneic BMT were reviewed in order to clarify the incidence, onset time, and risk factors for veno-occlusive disease (VOD) of the liver. Thirty-eight patients (27.1%) developed VOD diagnosed according to the Seattle clinical criteria. Seventeen patients developed VOD within 20 days of transplantation (early-onset) and in 21 patients developed after day 20 (late-onset) including eight patients with histological confirmation. Late-onset VOD occurred from day 21 to day 508 (median day 39). Moderate or severe VOD developed in 11 early-onset and 13 lateonset patients. Death occurred in eight early-onset and 10 late-onset patients. Serum albumin and cholinesterase levels prior to the start of pretransplant conditioning were significantly lower in early-onset VOD than in late-onset VOD. Multivariate analysis showed that low serum albumin levels (р3.7 g/dl) prior to the start of pretransplant conditioning was most strongly associated with the development of VOD. Donor mismatch (other than HLA-matched relatives), use of minocycline, and a long interval (у13 months) between diagnosis and BMT were also significantly associated with the development of VOD. In contrast, use of fosfomycin was associated with a decreased risk. Our data suggest that hepatic function reserve is important in the development and onset time of VOD. Veno-occlusive disease of the liver is a complication which may occur a long time after transplantation. Keywords: veno-occlusive disease (VOD); bone marrow transplantation (BMT); children; late onset; risk factor Veno-occlusive disease (VOD) of the liver is a clinical syndrome characterized by painful hepatomegaly, fluid retention and hyperbilirubinemia, and is a major early complication of BMT. In patients undergoing allogeneic BMT, it is the third cause of transplant-related death next to GVHD and infection.
Histologically, VOD is defined as the progressive and concentric narrowing of small intrahepatic venules associated with necrosis of hepatocytes in the centrilobular areas. 2, 3 However, the mechanisms and cellular events involved in VOD are not fully understood.
The diagnosis of VOD has generally been made according to the Seattle 4, 5 or Baltimore 1 clinical criteria, which are in good agreement with histologic data. In the Seattle study, 89% of patients with two or three of the specified clinical features ((1) jaundice, (2) hepatomegaly and/or right upper quadrant pain, and (3) ascites and/or unexplained weight gain) had histologic evidence of VOD vs 8% of those with none or only one of these features. 4 The incidence of VOD is reported as occurring in 1-54% of patients after BMT in studies with greater than 100 patients, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] and most studies have involved all age groups. Furthermore, the criteria of VOD usually include restriction of onset time, that is, 'within 20 days after transplantation' making it a complication that only occurs in the early phase. However, VOD after day 20 post-transplant has also been recognized. 8, 9, 16 We reviewed 140 allogeneic transplants in children with hematologic malignancies and analyzed the variables correlated with VOD including late-onset type to clarify the incidence, onset time and risk factors of this disease in children.
Materials and methods

Patient selection
Between January 1982 and May 1995, 145 children with hematologic malignancies underwent allogeneic BMT at the Nagoya University Hospital and the Japanese Red Cross Nagoya First Hospital. Five patients died of causes other than VOD within 30 days of transplant and were excluded from this analysis. As a result, 140 patients were reviewed. A clinical profile of patients in shown in Table 1 .
BMT procedure
All patients received high-dose chemotherapy with or without TBI. Conditioning regimens were as follows:
Bu (16 ) and CY (120 mg/kg) in one patient. Thus, 103 of the 140 patients received TBI (total dose 10-15 Gy) in their regimens. TBI was administered in four fractions at a rate of 5-7.5 cGy/min.
Prophylaxis for GVHD was generally MTX alone in the patients with HLA-matched sibling donors, and was shortterm MTX plus CsA 17 with or without anti-lymphocyte globulin or anti-thymocyte globulin in the patients with donors other than HLA-identical siblings. Five patients received grafts from donors with two or three HLA loci mismatch (three received T cell-depleted marrow, one received CD34-positive selected marrow, and one received unmanipulated marrow).
All patients were isolated in laminar air flow rooms and received oral non-absorbable antibiotics, oral acyclovir (ACV) and amphotericin B syrup. The day of bone marrow infusion was defined as 'day zero' and all post-transplant events were dated from this day. Informed consent for the transplant procedure and subsequent follow-up analysis was obtained from all patients and/or their parents or guardians.
Diagnosis of VOD
The diagnosis of VOD was made according to the Seattle clinical criteria, 5 which required at least two of the following three features: hyperbilirubinemia (total serum bilirubin Ͼ2 mg/dl or 34.2 mol/l), hepatomegaly or right upper quadrant pain of liver origin, and sudden weight gain (Ͼ2% of baseline body weight) because of fluid accumulation, along with no other explanation for these signs and symptoms. We eliminated restriction of onset time from the diagnostic criteria to investigate the putative existence of 'lateonset VOD' developing more than 20 days post transplant. VOD developing within 20 days after transplantation was designated as 'early-onset VOD'. Onset of VOD was defined as the day on which the second sign appeared, and recovery from VOD was defined as the day on which all signs resolved. VOD was scored as mild, moderate, or sev- ere, as described by McDonald et al. 5 Severe late-onset VOD was defined as requiring more than 100 days for recovery or any death occurring during VOD.
Histologic diagnosis was made as follows: paraffin blocks from the formalin-fixed liver were available in five patients with early-onset VOD (one autopsy; four needle necropsies) and eight patients with late-onset VOD (six autopsies, two needle necropsies). Histologic sections were stained with hematoxilin and eosin, Pa acid Schiff with and without diastase digestion, special stains for iron, reticulum, connective tissue (Masson's trichrome) and erastin. One of the authors (NH) blindly reviewed all the liver histology. VOD was said to be present if veins had concentric subendothelial thickening and luminal narrowing by either edematous reticulum fibers or collagen.
Risk factor analysis and statistical methods
We analyzed the following factors that were potentially related to the development of moderate or severe VOD in three categories: (1) Pretransplant factors: age, sex, diagnosis, leukemia status, number of transplants, interval between diagnosis and transplantation, past history of liver injury (maximum total serum bilirubin and maximum alanine aminotransferase (ALT)), liver status at the start of conditioning therapy (total serum bilirubin, ALT, albumin, and cholinesterase levels, as well as CMV infection and hepatomegaly); (2) Transplant procedural factors: conditioning regimen (number of agents, use of TBI, Bu and CY), donor type, GVHD prophylaxis; (3) Clinical course factors: development of acute GVHD, medications from the start of conditioning therapy to day 30 (imipenem/cilastatin or panipenem/betamipron, vancomycin, fosfomycin; minocycline, intravenous ACV, gancyclovir (GCV), intravenous amphotericin B, miconazole, and fluconazole). HBV and HCV were not included because no patient had serological evidence of these infections prior to BMT.
Risk factors for the development of moderate or severe VOD were analyzed by the 2 test. All significant factors were subsequently included in multivariate analysis according to the stepwise, step-up logistic regression model.
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Table 2
Characteristics of patients with early-onset VOD Age = years at transplant; pre-BMT = at the start of conditioning therapy; CR2 = 2nd complete remission; Re13 = 3rd relapse; IF = induction failure; Sib = HLA-matched sibling; UR = HLA-matched unrelated donor; 1mf = l locus mismatched father; m = mother; Tepa = thiotepa; LPAM = melphalan; VP16 = etoposide.
Results
Incidence and onset time of VOD
Of the 140 consecutive patients with hematologic malignancies undergoing allogeneic BMT, 38 developed VOD (27.1%), 17 had early-onset VOD and 21 had late-onset VOD. Late-onset VOD occurred from day 21 to day 508 (median day 39) (Figure 1 ).
Severity of VOD
Of the 38 patients with VOD, 14 (six early-onset and eight late-onset) had mild VOD, five (three and two) had moderate VOD, and 19 (eight and 11) had severe VOD. Moderate or severe disease developed in 11 of the 17 with early-onset VOD and 13 of the 21 patients with late-onset VOD. Among them, five and eight patients were histologically confirmed to have VOD, respectively. Eighteen patients (47.4% of the patients with VOD and 12.9% of all patients receiving BMT) died with VOD. The term 'died with VOD' is used rather than 'died of VOD' because it was often difficult to ascertain the exact cause of death. 1 Death occurred in eight of the 17 with early-onset VOD and 10 of the 21 patients with late-onset VOD.
Clinical characteristics of VOD
Clinical characteristics of 24 patients with moderate or severe VOD are shown in Tables 2 and 3 . All patients but one with late-onset VOD received TBI, and four of 11 patients with early-onset VOD and seven of 13 patients with lateonset VOD had moderate or severe acute GVHD. Eight patients with late-onset VOD received additional hepatotoxic drugs including ACV, GCV, amphotericin B, and anti-cancer agents. Importantly, serum albumin and cholinesterase levels were significantly lower prior to the start of conditioning in early-onset VOD (serum albumin (g/dl); 3.4-4.3, median 3.7, cholinesterase (⌬pH); 0.33-1.36, median 0.67) than late-onset VOD (serum albumin (g/dl); 3.6-4.8, median 4.0, cholinesterase (⌬pH); 0.78-1.27, Exclude mild VOD. Age = years at transplant; Serum albumin = mg/dl; Cholinesterase = delta pH; pre-BMT = at the start of conditioning therapy; pre-VOD = within 30 days before onset of VOD; CR3 = 3rd complete remission; Rel1 = 1st relapse; IF = induction failure; Sib = HLA-matched sibling; 1mc = 1 locus mismatched cousin; UR = HLA-matched unrelated donor; f = father; a = aunt; LPAM = melphalan; MIT = mitoxantrone; ACNU = nimustine; VP16 = etoposide; ADR = adriamycin; NE = not evaluated; ACV = acyclovir; GCV = gancyclovir; AMB = amphotericin B, ASP = 1-asparaginase; 6MP = 6-mercaptopurine. Case with recovery of VOD. TB = total bilirubin; ND = not determined; MOF = multiple organ failure; BO = bronchiolitis obliterance; BLPD = B lymphocyte proliferative disorder; DILPI = drug-induced liver parenchymal injury; aGVHD = acute GVHD; cGVHD = chronic GVHD; resp. = respiratory. median 0.92). In the patients with late-onset VOD, however, cholinesterase levels at the time prior to VOD significantly fell to 52% (range 35-95%) of the pretransplant value. Serum albumin levels also slightly decreased (85% (range 48-111%) of the pretransplant value).
The clinical features of late-onset VOD (excluding mild disease) are shown in Table 4 . In five patients the first symptom appeared within 20 days after transplant. Ten patients died with VOD within 45 days after the onset of VOD. Three patients recovered from 23 to 106 days. However, two of them died of leukemic relapse. Eight patients were histologically confirmed to have VOD. On histological examination, the outer layer of the affected veins often showed marked fibrous thickening, suggesting the presence of old VOD which had occurred subclinically.
Risk factors for VOD
Risk factors related to the development of moderate or severe VOD were evaluated by the 2 test. Among pretransplant factors, seven were significantly related to an increased risk of VOD, diagnosis of ALL (P = 0.02, compared with AML), advanced disease status (у3rd complete remission or relapse) in patients with acute leukemia (P = 0.002), longer interval (у13 months) between diagnosis and transplantation (P = 0.02), pretransplant history of elevated total serum bilirubin (у1.1 mg/dl) (P = 0.01), elevated total serum bilirubin (у1.1 mg/dl), and low albumin (р3.7 g/dl) and cholinesterase (р0.75̅ pH) levels at the start of conditioning therapy (P = 0.002, P Ͻ 0.0001, P = 0.0005, respectively).
Among transplant procedural factors, four were significantly related to an increased risk of VOD: greater number (у3) of pretransplant conditioning agents (P Ͻ 0.0001), use of TBI (P = 0.007), donor mismatch (other than HLAmatched relatives) (P = 0.002), and short-term MTX plus cyclosporine for GVHD prophylaxis (P = 0.005). Of the patients receiving lower doses of TBI (10 Gy), none developed VOD. Use of Bu and its dose were not associated with an increased risk of VOD.
Among clinical course factors, four were significantly related to an increased risk of VOD. Acute GVHD (P = 0.05) as well as use of minocycline, use of GCV and use of amphotericin B (P Ͻ 0.0001, P = 0.002, P = 0.02, respectively). Conversely, use of fosfomycin was associated with a decreased risk of VOD (P = 0.0009).
The factors shown to be significant by 2 analysis were further assessed by stepwise logistic regression multivariate analysis in the 110 patients with acute leukemia. As shown in Table 5 , a low serum albumin level prior to the start of conditioning therapy was most significantly associated with moderate or severe VOD (P = 0.0001). The second risk factor for VOD was donor mismatch (P = 0.008), followed by a long interval between diagnosis and BMT and use of minocycline during conditioning therapy to day 30 (P = 0.03 each). Conversely, use of fosfomycin was significantly associated with a decreased risk of VOD (P = 0.006). Table 5 Multivariate analysis of risk factors for moderate or severe VOD
Risk factors Odds ratio (95% CI) P value
Serum albumin level at the start of conditioning therapy (g/dl) 
Discussion
In the present series, VOD occurred in 27.1% of the patients. Incidence and mortality rate for post-transplant VOD varies markedly among institutions. The incidence ranged from 1 to 54%, even in studies with more than 100 patients. 1, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] This is due to differences in the definition of VOD in addition to differences in patient selection, type of transplantation, and conditioning regimen. If the Baltimore criteria 1 had been applied, the incidence of VOD in our study population would be 14.3%.
Late-onset VOD has not been clearly recognized in the literature to date. Blostein et al 19 reported that no patient developed VOD after day 21 post-transplant, and VOD is generally considered to be a complication that only occurs in the early phase. However, it has been reported that six out of 11 patients (54.5%) and 11 out of 30 patients (36.7%) developed VOD later than day 20 among pediatric patients undergoing autologous BMT. 8, 9 In the International Bone Marrow Transplant Registry study, about 30% of patients with VOD developed it later than day 20 after HLA-identical sibling transplants for leukemia. 20 Brugieres et al 8 reported that later onset VOD showed a worse prognosis, although this was not confirmed in the present study.
What is the difference in the mechanism of early-and late-onset VOD? One possible clue is the significant difference in serum albumin and cholinesterase levels prior to the start of conditioning, both of which were significantly decreased in the cases of early-onset VOD ( Table 3) . As VOD is due to damage to endothelial cells, sinusoids, and hepatocytes in zone 3 of the liver acinus, levels of serum albumin and cholinesterase only biosynthesized in the liver prior to the start of conditioning therapy could be one of the representatives of damage of these hepatic components. Moreover, as the most immediate cause of the damage is pretransplant conditioning therapy, the levels prior to the start of conditioning therapy should be critical. Namely, as low values of serum albumin and cholinesterase indicate reduced functional reserve of the liver, decreased pretransplant hepatic reserve in patients with early onset VOD might be related to its occurrence before day 20 post-transplant. On the other hand, although patients with normal pretransplant hepatic synthesizing capacity could initially tolerate the conditioning toxicity, post-transplant decrease in their hepatic reserve might become a risk factor for the later onset of VOD, possibly caused by the drugs used after transplantation.
A diagram of this concept is shown in Figure 2 . Earlyonset VOD has long been considered to be caused by potent conditioning therapy in patients with reduced hepatic function reserve. However, late-onset VOD may be of two types. In the first type, the onset is slightly delayed from day 20 because hepatic function reserve remains at the level of subclinical VOD until GVHD occurs and/or drugs promoting VOD are administered to treat infections and acute GVHD (patients 12-18 in Tables 3 and 4) . Another type involves patients in whom hepatic function reserve decreases after conditioning therapy and occurrence of GVHD, and exacerbates when drugs such as anti-viral 5 or anti-cancer agents are administered to treat infections and/or leukemia relapse (patients 20-24 in Tables 3 and 4) . This is considered to be true late-onset VOD. Some patients with the latter type of disease histologically showed old VOD and acute (active) VOD coexisting in two layers, and this suggests that late-onset VOD developed in two stages. Risk factors for VOD often differ between reports. In the present study, four factors were associated with an increased risk of moderate or severe VOD by multivariate analysis. Above all, low serum albumin prior to the start of conditioning therapy was most significantly associated with VOD. Serum albumin level was not extensively examined in most previous reports. 21, 22 Kami et al 22 reported that pseudocholinesterase levels before transplant were important markers of VOD, but albumin was not significantly low. However, it may be a good marker for liver functional reserve and nutritional condition because it is an essential nutritional element only biosynthesized in the liver, thus possibly being the most significant marker for predicting VOD. It may be consistent with the report 20 which shows the association between low performance status prior to the start of conditioning therapy and VOD.
Secondly, donors other than HLA-matched relatives were a significant risk factor for VOD, which is consistent with McDonald's report. 5 Infusion of alloimmune T cells may lead to greater cytokine release, contributing to liver toxicity. In fact, patients undergoing allogeneic BMT with T cell-depleted marrow are reported to have a low risk of VOD. 23 Thirdly, use of minocycline was associated with a high risk of VOD, and McDonald et al 5 stated that the reason for the high incidence of VOD in patients receiving vancomycin was that use of vancomycin implied presence of severe infection as much as the toxicity of vancomycin itself.
A long interval (у13 months) between diagnosis and BMT was also associated with an increased risk of moderate or severe VOD. This suggests that long exposure to agents toxic to the liver for underlying disease may subclinically decrease liver function.
Incidence of VOD was significantly lower in patients receiving fosfomycin. Fosfomycin has been used prophylactically or as initial treatment for mild infections in our institutes. Thus, the reason for the low incidence of VOD in patients receiving fosfomycin might be that the use of fosfomycin was associated with absence of severe infection rather than being an effect of fosfomycin itself. However, fosfomycin was recently found to inhibit the release of tumor necrosis factor-␣ 24 which is involved in the occurrence of VOD. 25, 26 Thus, it might be worth evaluating for the prophylaxis of VOD.
In conclusion, 'late-onset VOD' is a significant complication after BMT and may be related to the secondary damage to the liver caused by anti-viral agents and/or chemotherapy and conditioning agents. Low serum albumin prior to the start of conditioning therapy was the most significant factor associated with an increased risk of moderate or severe VOD, followed by donor mismatch, use of minocycline, and a longer interval between diagnosis and BMT. Use of fosfomycin was significantly associated with a decreased risk of VOD. We should be aware that VOD may occur a long time after transplanatation.
